Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

mHealth for Patient Self-Management of Opioid Use Disorder

Award Number: R42DA054881
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/14/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

mHealth for Patient Self-Management of Opioid Use Disorder - PROJECT SUMMARY / ABSTRACT The opioid crisis is an epidemic with devastating health, social, and economic consequences for the United States. From 1999–2018, almost 450,000 people died from an overdose involving any opioid, including prescription and illicit opioids. Three million US citizens and 16 million individuals worldwide have had or currently suffer from opioid use disorder (OUD). The total economic burden of the opioid crisis in the US is estimated to be more than $200 billion annually. Treatment for OUD involves medication assisted treatment (MAT) combined with counseling or behavioral therapy to manage the illness, achieve and sustain better health, and improve quality of life. Rates of recurrent drug use are high, and access to counseling is limited and costly. While MAT is standard of care and highly effective at reducing acute morbidity and mortality, there are advantages to treatment approaches tailored to address an individual patient’s drug use patterns and drug-related medical, psychiatric, and social problems. While mobile tools exist to support OUD treatment, these products offer only generalized information and not personalized feedback that is responsive to each person’s current status to support their individual recovery. In Phase I, we developed KIOS, an innovative software platform using nonlinear control theory. KIOS tracks multiple interacting symptoms (e.g., craving, mood, pain) to map patient trajectories and deliver timely evidence-based intervention strategies, responding directly to patient-reported needs. Accessible via mobile devices, KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during MAT. Phase I beta testing demonstrated significant reductions in key symptoms of OUD and high levels of engagement, usability and patient satisfaction. This project completes development of KIOS as a prescription digital health therapeutic suitable for FDA approval concomitant to MAT to treat OUD. This innovative tool to help patients manage OUD has the potential to have a profound impact on public health and achieve significant commercial success. This Phase II STTR study has three Specific Aims which are designed to attain FDA medical device approval: Specific Aim 1: Enhance Software Design and Features Specific Aim 2: Comply with Regulatory Requirements Specific Aim 3: Evaluate KIOS in a 12-week Randomized Controlled Trial


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	BIOMEDICAL DEVELOPMENT CORP	620 E DEWEY PL	SAN ANTONIO	TX	78212	BEXAR	USA	Drug Use and Addiction Research Programs	000	4	9/12/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $807,210 )
2023	2023	BIOMEDICAL DEVELOPMENT CORPORATION	499 E HIGH ST #401	LEXINGTON	KY	40507	FAYETTE	USA	Drug Use and Addiction Research Programs	001	4	8/17/2023	NON-COMPETING CONTINUATION	$685,922
2023	2023	BIOMEDICAL DEVELOPMENT CORPORATION	499 E HIGH ST #401	LEXINGTON	KY	40507	FAYETTE	USA	Drug Use and Addiction Research Programs	002	4	8/30/2023	NON-COMPETING CONTINUATION	$0
2023	2023	BIOMEDICAL DEVELOPMENT CORPORATION	499 E HIGH ST #401	LEXINGTON	KY	40507	FAYETTE	USA	Drug Use and Addiction Research Programs	000	3	4/26/2023	SUPPLEMENT FOR EXPANSION	$121,288
														Subtotal = $807,210

Issue Date FY: 2022 ( Subtotal = $947,945 )
2022	2022	BIOMEDICAL DEVELOPMENT CORPORATION	499 E HIGH ST #401	LEXINGTON	KY	40507	FAYETTE	USA	Drug Use and Addiction Research Programs	000	3	8/10/2022	NON-COMPETING CONTINUATION	$947,945
														Subtotal = $947,945

Issue Date FY: 2021 ( Subtotal = $866,907 )
2021	2021	BIOMEDICAL DEVELOPMENT CORPORATION	499 E HIGH ST #401	LEXINGTON	KY	40507	FAYETTE	USA	Drug Use and Addiction Research Programs	000	2	8/12/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$866,907
														Subtotal = $866,907

Grand Total All Awards = $2,622,062

Top

All Categories

About

Search

Reports

Data Submission

Award Information

mHealth for Patient Self-Management of Opioid Use Disorder

Award Number: R42DA054881

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/14/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer